For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
37
views
13
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      255
      similar
       All similar
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case

      case-report

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acne fulminans (AF) is a rare, acute, and severe form of acne vulgaris often associated with systemic symptoms. Its treatment is challenging and controversial. We report a case of isotretinoin-induced AF (IIAF) in a 12-year-old boy resistant to traditional therapies (oral steroids and isotretinoin). The patient was successfully treated with adalimumab that can be considered an effective off-label option in the treatment of resistant IIAF in children.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: not found
          • Article: not found

          Mechanistic target of rapamycin (mTOR) expression is increased in acne patients' skin.

          Giuseppe Monfrecola, Serena Lembo, Giuseppina Caiazzo … (2016)
          Article 0 comments Cited 34 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Acne fulminans: report of clinical findings and treatment of twenty-four patients.

            Seija-Liisa Karvonen (1993)
            Acne fulminans is an ulcerative form of acne with an acute onset and systemic symptoms. It most commonly affects adolescent boys.
            Article 0 comments Cited 16 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The treatment of acne fulminans: a review of 25 cases.

              D Seukeran, W Cunliffe (1999)
              The treatment of acne fulminans has been difficult. It is difficult to perform a controlled treatment trial due to the rarity of the complication. However, it is possible to compare four different therapeutic regimens which have evolved with time in the management of 25 patients over a period of 25 years. Oral antibiotics produced a slow response in the resolution of acne and systemic symptoms. The addition of a systemic steroid produced a quick resolution of systemic features, but the time until resolution of the acne was longer than when it was used in combination with oral isotretinoin. The protocols which used a combination of prednisolone and isotretinoin led to faster control of systemic features as well as clearance of acne when compared with other protocols. This was particularly so if the oral steroid was used sooner rather than later. We conclude that the preferred treatment of acne fulminans is oral prednisolone 0.5-1 mg/kg daily for 4-6 weeks (thereafter slowly reduced to zero) with oral isotretinoin being added to the regimen at the fourth week, initially at 0.5 mg/kg daily and gradually increased to achieve complete clearance.
              Article 0 comments Cited 16 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (publisher-id): SAD
                Journal ID (pmc): SAD
                Journal ID (doi): 10.1159/issn.2296-9160
                Title: Skin Appendage Disorders
                Publisher: S. Karger AG
                ISSN (Print): 2296-9195
                ISSN (Electronic): 2296-9160
                Publication date Subscription-year: 2021
                Publication date (Print): February 2021
                Publication date (Electronic): 21 January 2021
                Volume: 7
                Issue: 2
                Pages: 115-119
                Affiliations
                Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
                Author notes
                *Elisa Camela, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, IT–80131 Naples (Italy), elisacamela@gmail.com
                Article
                Publisher ID: 512032 Other ID: Skin Appendage Disord 2021;7:115–119
                DOI: 10.1159/000512032
                PubMed ID: 33796557
                SO-VID: fd2cb4ca-89a2-4646-85c1-521505732676
                Copyright © © 2021 S. Karger AG, Basel
                License:

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Date received : 15 May 2020
                Date accepted : 05 October 2020
                Page count
                Figures: 3, Pages: 5
                Categories
                Subject: Novel Insights from Clinical Practice

                ScienceOpen disciplines: Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
                Keywords: Acne fulminans,Treatment,Isotretinoin,Adalimumab
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy, Pathology, Surgery, Dermatology, Pharmacology & Pharmaceutical medicine
                Keywords: Acne fulminans, Treatment, Isotretinoin, Adalimumab

                Comments

                Comment on this article

                scite_

                Similar content255

                See all similar

                Cited by2

                See all cited by

                Most referenced authors95

                See all reference authors